A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

I4D-MC-JTJL -

The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Advanced Cancer
What the trial is testing?
Prexasertib; Ralimetinib
Could I receive a Placebo?
No
Enrollment Goal
9
Trial Dates
Aug 10, 2016 - May 15, 2017
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.